ClinicalTrials.gg
WithdrawnNCT01445275Updated Aug 21, 2024

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

An observational study in Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome and Ovarian Carcinoma, sponsored by Gynecologic Oncology Group. Withdrawn at 1 site in United States. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Gynecologic Oncology Group · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
0
Ages
30 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group — none open to participants now, none under way, none of them phase 3. Fallopian Tube Neoplasms · Gynecologic Oncology Group.

Started
2011
with 5 others
Observational
9 of 41
none open now
Registered
38th of 41
by date

Among the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group, this one is one of 6 that started in 2011, is one of 9 observational ones, and was the 38th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

None of the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group is open now. The open studies under Fallopian Tube Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 30 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group as a file.
02

Study summary

This research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the Gynecology Oncology Group (GOG)-0199 trial. Gathering information about women at elevated genetic risk for ovarian cancer may help doctors learn more about risk reduction procedures and the cost of these procedures.

Read the detailed description

PRIMARY OBJECTIVES:

I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of risk-reducing salpingo-oophorectomy (RRSO) versus ovarian cancer screening (OCS) for women at elevated genetic risk of ovarian cancer over a five-year period, using data from GOG-0199 to model survival.

SECONDARY OBJECTIVES:

I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of RRSO versus OCS for women at elevated genetic risk of ovarian cancer over a lifetime, using stage-specific cohorts and population-based data to model long-term survival. (Exploratory) II. To use value of information (VOI) methodology to set future research priorities aimed at developing evidence-based approaches to the management of women who are at elevated genetic risk of ovarian cancer. (Exploratory)

OUTLINE:

Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.

03

Conditions studied

  • Fallopian Tube Carcinoma
  • Hereditary Breast and Ovarian Cancer Syndrome
  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ovarian cancer who participated in GOG-0199

Eligibility criteria

Inclusion Criteria:

  • Women who were eligible and evaluable for GOG-0199, a prospective, non-randomized, natural history study
  • Data collected from GOG-0199 available
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
0 participants (actual)

Groups and cohorts

  • Ancillary-Correlative (Health Services Research)

    Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.

    Procedure: Evaluation of Cancer Risk Factors · Other: Medical Chart Review · Other: Study of Socioeconomic and Demographic Variables

Interventions

  • ProcedureEvaluation of Cancer Risk Factors

    Ancillary studies

    Also known as: cancer risk factors evaluation

  • OtherMedical Chart Review

    Ancillary study

    Also known as: Chart Review

  • OtherStudy of Socioeconomic and Demographic Variables

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Cost-effectiveness of RRSO versus OCS

    Incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers in the OCS arm and in the RRSO arm will be collected. This information will be obtained from the CANCER UPDATE FORM (CA-0199) and the Ovarian Surgery Form (C-0199). Summary of the number and timing of screening serum tests, pelvic ultrasound, and surgery procedures will be used to calculate costs, and will be incorporated into the model of Markov stage that corresponds to the study timepoint at which these studies were performed.

    Time frame: 6 months

07

Study locations

1 site
  • Gynecologic Oncology Group
    Philadelphia, Pennsylvania 19103, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2011; primary completion for Jan 2016, 60 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2011
First posted
Oct 3, 2011
StartEst.
Jan 2011
Primary completionEst.
Jan 2016
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01445275
Responsible party
Sponsor
First posted
Oct 3, 2011
Start date
Jan 2011 (estimated)
Primary completion
Jan 2016 (estimated)
Last update
Aug 21, 2024

Study contacts

Laura Havrilesky
principal investigator · Gynecologic Oncology Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion